Literature DB >> 23814641

Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test.

Gang Han1, Michael J Schell, Jongphil Kim.   

Abstract

The exact two-sided likelihood ratio test for testing the equality of two exponential means is proposed and proved to be the uniformly most powerful unbiased test. This exact test has advantages over two alternative approaches in that it is unbiased and more powerful while maintaining the type I error. The use of the proposed test is demonstrated in a non-small cell lung cancer clinical trial design.

Entities:  

Keywords:  Survival analysis; exponential family; power calculation; uniformly most powerful unbiased test

Year:  2012        PMID: 23814641      PMCID: PMC3693095          DOI: 10.1080/19466315.2012.698945

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  3 in total

1.  What price Kaplan-Meier?

Authors:  R G Miller
Journal:  Biometrics       Date:  1983-12       Impact factor: 2.571

2.  Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.

Authors:  George R Simon; Michael J Schell; Mubeena Begum; Jongphil Kim; Alberto Chiappori; Eric Haura; Scott Antonia; Gerold Bepler
Journal:  Cancer       Date:  2011-10-25       Impact factor: 6.860

3.  Connexin 43 is a potential prognostic biomarker for ewing sarcoma/primitive neuroectodermal tumor.

Authors:  Marilyn M Bui; Gang Han; Geza Acs; Damon Reed; Ricardo J Gonzalez; T L Pasha; Paul J Zhang
Journal:  Sarcoma       Date:  2011-05-08
  3 in total
  4 in total

1.  Improved survival modeling in cancer research using a reduced piecewise exponential approach.

Authors:  Gang Han; Michael J Schell; Jongphil Kim
Journal:  Stat Med       Date:  2013-07-30       Impact factor: 2.373

2.  Testing violations of the exponential assumption in cancer clinical trials with survival endpoints.

Authors:  Gang Han; Michael J Schell; Heping Zhang; Daniel Zelterman; Lajos Pusztai; Kerin Adelson; Christos Hatzis
Journal:  Biometrics       Date:  2016-09-26       Impact factor: 2.571

3.  Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.

Authors:  Naoko I Simonds; Muin J Khoury; Sheri D Schully; Katrina Armstrong; Wendy F Cohn; David A Fenstermacher; Geoffrey S Ginsburg; Katrina A B Goddard; William A Knaus; Gary H Lyman; Scott D Ramsey; Jianfeng Xu; Andrew N Freedman
Journal:  J Natl Cancer Inst       Date:  2013-05-09       Impact factor: 13.506

4.  Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Authors:  Kerin Adelson; Bhuvaneswari Ramaswamy; Joseph A Sparano; Paul J Christos; John J Wright; George Raptis; Gang Han; Miguel Villalona-Calero; Cynthia X Ma; Dawn Hershman; Joseph Baar; Paula Klein; Tessa Cigler; G Thomas Budd; Yelena Novik; Antoinette R Tan; Susan Tannenbaum; Anupama Goel; Ellis Levine; Charles L Shapiro; Eleni Andreopoulou; Michael Naughton; Kevin Kalinsky; Sam Waxman; Doris Germain
Journal:  NPJ Breast Cancer       Date:  2016-12-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.